Breaking the Transposase Monopoly: NEB and seqWell Democratize Tagmentation

IPSWICH, Mass. – October 15, 2026 — Genomics is often celebrated for its massive data outputs and plummeting sequencing costs, but behind the curtain of these triumphs lies a quieter, more stubborn bottleneck: the proprietary reagents required to prepare DNA for the sequencer. For years, researchers pushing the boundaries of single-cell biology and custom assay development have been constrained by the limitations of commercial library preparation kits. Today, a new strategic partnership aims to dismantle that bottleneck.

New England Biolabs (NEB) and Beverly-based genomic workflow pioneer seqWell have announced the commercial launch of TnX Transposase (Unloaded), a move that promises to democratize one of the most critical steps in next-generation sequencing (NGS). Under the new agreement, NEB has secured co-exclusive global rights to sell the engineered enzyme, as well as the rights to manufacture and integrate TnX into its own extensive portfolio of molecular biology products.

The Invisible Bottleneck of Modern Genomics

To understand the significance of this partnership, one must look at the mechanics of NGS library preparation. The workhorse of this process is often the Tn5 transposase, the biological engine behind a technique known as tagmentation. Tagmentation is an elegant, single-step reaction that simultaneously fragments nucleic acids and inserts adapter sequences, effectively bypassing hours of tedious enzymatic fragmentation, end-repair, and ligation steps.

However, the commercial landscape for tagmentation has long been dominated by heavily patented, pre-packaged solutions, most notably Illumina’s Nextera product lines. While these kits are highly effective for standard, high-throughput applications, they are expensive and notoriously inflexible. Researchers developing novel multi-omics protocols or custom single-cell assays often find themselves locked into vendor-specific adapter sequences.

To escape this vendor lock-in, many laboratories have resorted to "homebrew" protocols, sourcing unloaded Tn5 transposases from various alternative suppliers to assemble their own custom transposomes. Yet, this do-it-yourself approach introduces a new set of perilous challenges, primarily centered around enzyme reliability and the reproducibility of the resulting data.

Engineering Out the Reproducibility Crisis

The wild-type and standard hyperactive variants of Tn5 are notoriously finicky. Bench scientists frequently battle lot-to-lot variability, unpredictable fragment size distributions, and a rapid loss of enzyme activity following standard freeze-thaw cycles. More critically, standard Tn5 exhibits a pronounced sequence insertion bias, meaning it does not integrate adapters uniformly across the genome.

In highly sensitive applications like ATAC-seq (Assay for Transposase-Accessible Chromatin using sequencing), where researchers map the open, active regions of the genome using picogram-level DNA inputs from single cells, this bias can severely skew data interpretation and mask crucial biological insights.

SeqWell’s TnX enzyme was engineered specifically to solve these pain points. Developed through more than twenty cycles of directed evolution, the engineered variant boasts higher baseline activity, enhanced thermal robustness, and a significantly reduced insertion bias compared to its Tn5 predecessors.

"We're excited to provide researchers with a highly reproducible transposase that gives them freedom over adaptor design," said Isaac Meek, Director of Business Development at NEB. "By combining seqWell's innovative TnX enzyme with NEB's fifty-plus years of excellence in manufacturing and quality control, we are delivering a versatile, unloaded enzyme that solves lot variability issues common to unloaded Tn5 transposases and achieves stringent quality standards for broader research applications."

The Power of the "Unloaded" Enzyme

By supplying the TnX enzyme "unloaded"—without pre-attached DNA adapters—the NEB-seqWell partnership places the power of assay design directly back into the hands of the researcher. End-users can now load the enzyme with their own custom-designed mosaic-end oligonucleotides.

This flexibility is the bedrock of modern genomic innovation. Whether a lab is incorporating unique molecular identifiers (UMIs) for ultra-rare variant detection in oncology, designing complex spatial transcriptomics workflows, or building multi-omics assays that simultaneously read DNA and epigenetic markers from a single cell, custom adapter design is a non-negotiable requirement.

Furthermore, this approach is fundamentally platform-agnostic. While historical tagmentation tools were tightly coupled to specific sequencing hardware, the unloaded TnX system allows researchers to build libraries compatible with virtually any major sequencing platform. Industry analysts note that this modularity is essential as the market diversifies beyond traditional short-read sequencing, accommodating emerging technologies from PacBio, Element Biosciences, Complete Genomics, and Ultima Genomics.

Scaling Up: The Commercial Mechanics

The agreement grants NEB co-exclusive global rights to sell the TnX Transposase, which is now available directly through their catalog complete with optimized loading protocols. Crucially, the deal also secures NEB the right to manufacture the enzyme and integrate it into its own NEBNext library preparation solutions.

For seqWell, aligning with a manufacturing titan like NEB provides an immediate, massive expansion of their global footprint.

"Partnering with New England Biolabs is a significant milestone for seqWell and for the genomics community at large," said Joe Mellor, Chief Scientific Officer at seqWell. "NEB has long been synonymous with quality and reliability in enzyme tools for life science research — that legacy makes them the ideal partner to bring TnX to a wider audience. We are excited to combine NEB's trusted manufacturing scale with seqWell's expertise in transposase technology to ensure researchers everywhere have access to best-in-class tools."

SeqWell will continue to market its own portfolio of loaded, TnX-based library preparation kits, such as ExpressPlex and MosaiX. The Massachusetts-based company has aggressively pursued a collaborative commercial strategy in recent years, evidenced by key partnerships with Codexis for enzyme optimization, Complete Genomics for automated workflows, and PacBio for long-read sequencing applications.

The global next-generation sequencing market is projected to surpass $73 billion by 2034. A significant portion of that economic engine relies on the unglamorous, foundational reagents used in the earliest stages of sample preparation. When a critical reagent like a transposase is monopolized or technically flawed, it acts as a tax on innovation—both in actual dollars spent on failed library preparations and in the invisible cost of experiments that were never attempted due to technical limitations.

By decoupling the core enzyme from the proprietary adapter payload, NEB and seqWell are effectively open-sourcing the creative potential of tagmentation. Genomics core facility directors, who are often tasked with stretching limited grant funding across diverse, highly customized research projects, stand to be the immediate beneficiaries. Instead of navigating the complex intellectual property landscape of commercial kits or struggling with the batch-to-batch unreliability of standard Tn5, these facilities now have access to a standardized, highly engineered alternative manufactured at a global scale.

The shift toward modular, high-performance biological tools reflects a maturing genomics industry. In the early days of next-generation sequencing, closed-loop systems were necessary to guarantee user success. Today, the end-users are highly sophisticated method developers who require raw, reliable components to build the next generation of diagnostics and therapeutics. As the barriers to custom assay development fall, the pace of discovery is poised to accelerate, driven not just by better sequencers, but by the quiet revolution happening inside the reagent tube.